Format

Send to

Choose Destination
Hematol Oncol Clin North Am. 2011 Oct;25(5):951-66, v. doi: 10.1016/j.hoc.2011.09.001. Epub 2011 Oct 19.

Hurdles toward a cure for CML: the CML stem cell.

Author information

1
Section of Experimental Haematology, Cancer Division, Faculty of Medicine, University of Glasgow, Paul O'Gorman Leukaemia Research Centre, Gartnavel General Hospital, 1053 Great Western Road, Glasgow, G12 0YN, UK.

Abstract

Chronic myeloid leukemia (CML) is the first cancer in which a genetic alteration was proven to be of pathogenic significance and is considered a disease model for oncogene addiction, targeted therapy, and cancer stem cells (CSCs). The introduction of tyrosine kinase inhibitors (TKIs) resulted in dramatic improvement in response and survival for patients with CML in chronic phase (CP); however, CSCs are spared by TKIs. In this article, we review the role of CSCs in CML in CP, their persistence following TKI treatment, and current approaches to target this population in an attempt to achieve disease cure.

PMID:
22054728
DOI:
10.1016/j.hoc.2011.09.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center